Published in Oncologist on May 13, 2013
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer | NCT01347788
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (PROCEED) | NCT01306890
Sipuleucel-T Manufacturing Demonstration Study | NCT01477749
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci (2015) 0.84
Resistance to "castration-resistant". Oncologist (2014) 0.82
An update on enzalutamide in the treatment of prostate cancer. Ther Adv Urol (2015) 0.79
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Int J Oncol (2016) 0.79
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. Adv Ther (2016) 0.78
Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget (2016) 0.77
Biological characteristics of prostate cancer cells are regulated by hypoxia-inducible factor 1α Oncol Lett (2014) 0.76
IMPACT Study: Targeted Prostate Cancer Screening. Oncologist (2013) 0.75
In reply. Oncologist (2014) 0.75
Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes (2017) 0.75
Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings. Patient (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer (2008) 15.20
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet (1995) 6.60
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst (2004) 5.87
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer (2008) 2.86
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
European cancer mortality predictions for the year 2013. Ann Oncol (2013) 2.71
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate (2011) 2.21
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem (2010) 1.97
End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol (2011) 1.94
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2009) 1.85
Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem (2002) 1.80
Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract (2011) 1.75
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer (2012) 1.64
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.64
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology (2011) 1.63
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate (2010) 1.59
Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol (2003) 1.58
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol (2008) 1.57
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology (Williston Park) (2012) 1.49
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Chemotherapy for advanced prostate cancer: 25 years later. J Clin Oncol (2008) 1.38
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis (2008) 1.32
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol (2004) 1.31
Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res (2010) 1.30
Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol (2011) 1.30
Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev (1999) 1.30
Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness? Br J Cancer (2012) 1.27
T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19
Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am J Clin Oncol (1997) 1.18
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res (2011) 1.11
Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (2010) 1.05
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol (2007) 1.05
Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer (2005) 1.01
Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol (2010) 0.99
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology (2012) 0.98
Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncol Rep (2006) 0.97
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.95
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets (2012) 0.91
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int (2012) 0.90
Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci (2012) 0.88
The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer (2009) 0.84
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate (2011) 0.84
Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review. Cancer Treat Rev (2012) 0.84
Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol (2012) 0.83
Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon? EPMA J (2012) 0.81
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int (2012) 0.81
Optimizing the management of prostate cancer in senior adults: call to action. Oncologist (2012) 0.81
Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). BJU Int (2012) 0.80
[Transforming growth factor β in prostate cancer: cellular effects and basic molecular mechanisms]. Urologe A (2013) 0.76
EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol (2013) 7.48
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol (2010) 7.20
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol (2011) 4.01
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol (2011) 3.96
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med (2012) 3.44
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol (2011) 3.32
Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol (2013) 3.20
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol (2010) 2.80
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol (2007) 2.79
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis. Anesthesiology (2008) 2.75
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol (2008) 2.56
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol (2012) 2.31
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Side-effects of treatments for locally advanced prostate cancer. BJU Int (2006) 2.03
Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol (2011) 1.92
Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study. Arch Gen Psychiatry (2007) 1.89
Early outcomes of active surveillance for localized prostate cancer. BJU Int (2005) 1.84
ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol (2011) 1.80
Toxicities of targeted therapy and their management in kidney cancer. Eur Urol (2011) 1.76
Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res (2007) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Benign prostatic hyperplasia: counting the cost of its management. BJU Int (2010) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Optimising repeat prostate biopsy decisions and procedures. BJU Int (2011) 1.62
The enigmatic planctomycetes may hold a key to the origins of methanogenesis and methylotrophy. Mol Biol Evol (2004) 1.56
Heat shock proteins: their role in urological tumors. J Urol (2003) 1.56
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
Indicators for research performance evaluation: an overview. BJU Int (2012) 1.56
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU Int (2004) 1.53
Dying trajectories in heart failure. Palliat Med (2007) 1.53
Diethylstilbestrol in castration-resistant prostate cancer. BJU Int (2012) 1.49
Impact of surgeon volume on the morbidity and costs of radical cystectomy in the USA: a contemporary population-based analysis. BJU Int (2015) 1.47
Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol (2006) 1.44
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail? Eur Urol (2008) 1.43
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Radical prostatectomy vs watchful waiting. BJU Int (2005) 1.41
Can lifestyle modification lower the risk of prostate cancer? BJU Int (2010) 1.40
Current prospects for the chemoprevention of prostate cancer. BJU Int (2010) 1.39
Are the National Institute for Health and Clinical Excellence guidelines that promulgate active surveillance for low-risk prostate cancer justified by the available evidence? BJU Int (2008) 1.39
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer (2003) 1.35
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol (2011) 1.33
TGF-beta1-induced EMT can occur independently of its proapoptotic effects and is aided by EGF receptor activation. Am J Physiol Renal Physiol (2005) 1.33
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
Isolation of Gemmata-like and Isosphaera-like planctomycete bacteria from soil and freshwater. Appl Environ Microbiol (2002) 1.29
EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer (2009) 1.28
Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol (2013) 1.24
Communication in heart failure: perspectives from older people and primary care professionals. Health Soc Care Community (2006) 1.21
Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology (2010) 1.20
Inequalities in the primary care of patients with coronary heart disease and serious mental health problems: a cross-sectional study. Heart (2007) 1.19
Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int (2010) 1.16
Prostate epithelial cell differentiation and its relevance to the understanding of prostate cancer therapies. Clin Sci (Lond) (2005) 1.16
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev (2010) 1.16
Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate (2002) 1.15
Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate (2007) 1.10
The requirements of a specialist Prostate Cancer Unit: a discussion paper from the European School of Oncology. Eur J Cancer (2010) 1.10
What is low-risk prostate cancer and what is its natural history? World J Urol (2008) 1.09
Electronic learning can facilitate student performance in undergraduate surgical education: a prospective observational study. BMC Med Educ (2005) 1.09
Predictors of the quality of life of older people with heart failure recruited from primary care. Age Ageing (2006) 1.07
Biomarker research in prostate cancer--towards utility, not futility. Nat Rev Urol (2011) 1.07
Epidemiology of testicular cancer. BJU Int (2009) 1.06
Does active surveillance for men with localized prostate cancer carry psychological morbidity? BJU Int (2007) 1.05
Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine (Phila Pa 1976) (2002) 1.04
Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases. Nucl Med Commun (2012) 1.04
Eukaryotic signature proteins of Prosthecobacter dejongeii and Gemmata sp. Wa-1 as revealed by in silico analysis. FEMS Microbiol Lett (2005) 1.03
18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res (2011) 1.03
BMI and the risk of renal cell carcinoma. Curr Opin Urol (2011) 1.03
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. Curr Oncol Rep (2012) 1.03
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer (2010) 1.02
Current vaccination strategies for prostate cancer. Eur Urol (2011) 1.01
Recruiting older people into a large, community-based study of heart failure. Chronic Illn (2005) 1.01
Predicting mortality among a general practice-based sample of older people with heart failure. Chronic Illn (2008) 1.00
Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma. Kidney Int (2004) 1.00
Predictors of histological disease progression in untreated, localized prostate cancer. J Urol (2007) 1.00
Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood (2003) 1.00
Patient views of social service provision for older people with advanced heart failure. Health Soc Care Community (2007) 0.98
Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices. Hematol Oncol Clin North Am (2011) 0.98
Gender differences in the renin-angiotensin and nitric oxide systems: relevance in the normal and diseased kidney. Kidney Blood Press Res (2007) 0.98
Dying, death and bereavement: a qualitative study of the views of carers of people with heart failure in the UK. BMC Palliat Care (2009) 0.98
2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res (2009) 0.98
Exploring mechanisms involved in renal tubular sensing of mechanical stretch following ureteric obstruction. Am J Physiol Renal Physiol (2008) 0.98
Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists. BJU Int (2006) 0.97
Mhp493 (P216) is a proteolytically processed, cilium and heparin binding protein of Mycoplasma hyopneumoniae. Mol Microbiol (2008) 0.97
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers. Cancer Biol Ther (2009) 0.97
Delayed graft function: a dilemma in renal transplantation. BJU Int (2005) 0.97
Androgen-mediated resistance to apoptosis. Prostate (2002) 0.97
Radium-223 in prostate cancer. N Engl J Med (2013) 0.97